Objective-This post hoc analysis of the CSPPT (China Stroke Primary Prevention Trial) assessed the individual variation in total homocysteine (tHcy)-lowering response after an average 4.5 years of 0.8 mg daily folic acid therapy in Chinese hypertensive adults and evaluated effect modification by methylenetetrahydrofolate reductase (MTHFR) C677T genotypes and serum folate levels. Approach and Results-This analysis included 16 413 participants from the CSPPT, who were randomly assigned to 2 double-blind treatment groups: either 10-mg enalapril+0.8-mg folic acid or 10-mg enalapril, daily and had individual measurements of serum folate and tHcy levels at baseline and exit visits and MTHFR C677T genotypes. Mean baseline tHcy levels were comparable between the 2 treatment groups (14.5±8.5 versus 14.4±8.1 μmol/L; P=0.561). After 4.5 years of treatment, mean tHcy levels were reduced to 12.7±6.1 μmol/L in the enalapril+folic acid group, but almost stayed the same in the enalapril group (14.4±7.9 μmol/L, group difference: 1.61 μmol/L; 11% reduction). More importantly, tHcy lowering varied by MTHFR genotypes and serum folate levels. Compared with CC and CT genotypes, participants with the TT genotype had a more prominent L-shaped curve between tHcy and serum folate levels and required higher folate levels (at least 15 ng/mL) to eliminate the differences in tHcy by genotypes. Conclusions-Compared with CC or CT, tHcy in the TT group manifested a heightened L-shaped curve from low to high folate levels, but this difference in tHcy by genotype was eliminated when plasma folate levels reach ≈15 ng/mL or higher. Our data raised the prospect to tailor folic acid therapy according to individual functional mutation affecting key enzyme activity in tHcy metabolism. Previous studies found a variable degree of tHcy reduction in response to FA therapy, ranging from 10% to 38% across studies [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] ; the reasons for such variability are not well understood. The TT genotype has been associated with elevated tHcy levels in populations with low folate intake.
levated blood total homocysteine (tHcy) level is a wellrecognized and modifiable risk factor for cerebral and cardiovascular disease. [1] [2] [3] [4] In particular, hypertension accompanied by elevated tHcy can synergistically increase the risk of stroke. [5] [6] [7] Thus, it is important to safely and effectively lower tHcy in hypertensive patients to reduce stroke and cardiovascular morbidities and mortality. Elevated tHcy may be because of insufficient folate intake and a methylenetetrahydrofolate reductase (MTHFR) gene variant. 8, 9 However, previous tHcy-lowering trials [10] [11] [12] [13] [14] [15] [16] have not considered whether and to what degree these factors could modify the efficacy of folic acid (FA) treatment.
This study aimed to examine important factors affecting individual response to FA therapy, paying particular attention to serum folate status and the MTHFR C677T genotype, a functional mutation affecting key enzyme activity in tHcy metabolism. Previous studies found a variable degree of tHcy reduction in response to FA therapy, ranging from 10% to 38% across studies [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] ; the reasons for such variability are not well understood. The TT genotype has been associated with elevated tHcy levels in populations with low folate intake. 28 However, it is unclear whether individuals with MTHFR 677CC, CT, or TT genotypes respond differently to FA treatment. To address these questions, it is ideal to use populations with high rates of the MTHFR 677TT variant and without FA fortification.
Thus, we conducted a post hoc analysis of the data from the CSPPT (China Stroke Primary Prevention Trial), 29 in which participants were hypertensive adults aged 45 to 75 years without pre-existing stroke and major cardiovascular events. Of note, China is a country with a high rate of the MTHFR C677T mutation and without a mandatory FA fortification program, allowing us to examine a wide spectrum of folate levels, including low levels across the genotypes. We aimed to delineate the variability of tHcy lowering in response to long-term FA therapy (0.8 mg/d) and to determine to what degree serum folate levels and the MTHFR C677T genotype jointly modify the FA therapeutic effect.
The CSPPT, with the availability of individual serum folate and tHcy measurements at the baseline and exit visits, as well as the MTHFR C677T genotype, offers an exceptional opportunity to study the effect of gene-folate interactions on the tHcy-lowering response to FA treatment. Such data are critically needed to develop a cost-effective and safe FA regimen that is tailored to individual genetic background and folate nutritional status.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement. Briefly, this post hoc analysis included 16 413 hypertensive men and women from the CSPPT, with data on baseline and exit serum folate and tHcy levels, as well as the MTHFR C677T genotype. A detailed description and primary results of the CSPPT have been reported elsewhere.
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Results
Participants and Baseline Characteristics
As illustrated in the flow chart ( Figure 1 ) 20 702 participants of the CSPPT were enrolled and randomized between May 2008 and August 2009. A total of 10 348 participants were assigned to the enalapril+FA (a single pill combination) group and 10 354 were assigned to the enalapril group. Participants with missing data on serum folate and tHcy measurements at either the baseline visit (n=421) or at the exit visit (n=3868) were excluded from this report. The final analyses included a total of 16 413 subjects (n=8218 in the enalapril+FA group and n=8195 in the enalapril-only group).
The frequency of the MTHFR C677T polymorphisms was 27% (n=4442) for CC, 49% (n=8053) for CT, and 24% (n=3918) for TT among the included participants. A similar frequency of the MTHFR C677T genotype was observed between the 2 treatment groups.
Additionally, the baseline characteristics and the MTHFR C677T genotype distribution of participants included in the final analyses were similar to those excluded from the final analyses (Table I in the online-only Data Supplement).
Effect of FA Therapy on Serum Folate Levels and tHcy Levels
Changes in folate levels (Δ folate) and tHcy levels (Δ Hcy) after treatment were calculated by subtracting exit folate or tHcy levels from baseline folate or tHcy levels. As shown in Table 1 , the mean baseline folate levels were comparable between the 2 treatment groups (enalapril group, 8.5±3.8 ng/ mL; enalapril+FA group, 8.5±3.9 ng/mL). At the exit visit, serum mean folate concentrations increased to 13.1±5.9 ng/mL in the enalapril group and 24.7±19.2 ng/mL in the enalapril+FA group (group difference: 11.52 ng/mL; 95% confidence interval [CI], 11.08-11.95 ng/mL). The group difference for mean folate change did not vary substantially by MTHFR C677T genotype: 11.78, 11.53, and 11.18 ng/mL in the MTHFR 677CC, CT, and TT genotypes, respectively.
Mean baseline tHcy levels were comparable between the 2 groups (enalapril group, 14.5±8.5 μmol/L; enalapril+FA group, 14.4±8.1 μmol/L; P=0.561). After a median of 4.5 years of FA treatment, tHcy levels were similar to baseline level in the enalapril group (14.4±7.9 μmol/L) but were significantly reduced in the enalapril+FA group (12.7±6.1 μmol/L; group difference: −1.61 μmol/L; 95% CI, −1.83 to 1.39 μmol/L; 11% reduction on average).
Effect Modification of MTHFR C677T Genotype and Serum Folate Levels on tHcy-Lowering Response to FA Treatment
When participants were stratified by the MTHFR C677T genotype, the effect of FA treatment on tHcy lowering varied considerably by genotype ( Participants in the per-protocol set (n=12 638, participants with no major deviation from the protocol and with an overall compliance rate of 70% or higher at the end of the study) exhibited a similar pattern of tHcy-lowering effect, but with a slightly larger group difference (Table II in the online-only Data Supplement).
Most interestingly, the effect of the MTHFR C677T genotype on tHcy was dependent on serum folate levels. As illustrated in Figure 2 , when folate levels were low, the TT genotype had the greatest effect on tHcy levels. Because serum folate levels increased, the effect of the MTHFR 677TT variant on tHcy diminished. This was true for both the baseline (Figure 2A ) and the exit visit ( Figure 2B) . A test for MTHFR C677T genotype-folate level interaction was statistically significant (P<0.01; Table III in the online-only Data Supplement). We also performed additional interaction analysis of FA supplementation and MTHFR C677T genotype (Table IV in the online-only Data Supplement). Our data showed that TT genotype significantly modified the tHcy-lowering effect of FA supplementation, as assessed by tHcy at exit and tHcy change from baseline, and such effect modification was more pronounced among participants with low baseline folate.
Our data suggest a threshold for serum folate (around 15 ng/mL or 34 nmol/L), where the effect of the TT genotype on tHcy levels was eliminated. Figure 3 further illustrates that the differences in tHcy levels between the TT and CC genotypes and between the TT and CT genotypes approach to null when serum folate levels reach ≥15 ng/mL. Table 2 shows that after FA treatment, ≈30% of participants with TT genotype did not achieve folate threshold of ≥15 ng/ mL. It matters because those with the TT genotype must surpass the folate threshold to overcome the genetically induced MTHFR enzyme defect. Of further interest, only 20% of participants from the TT group achieved target tHcy levels (<10 μmol/L) at the exit visit. In a sensitivity analysis using the per-protocol set, the percentage slightly improved, but the general pattern remained the same (Table V in the online-only Data Supplement).
Is There Room to Further Lower Serum tHcy?
Taken together, our data indicate that compared with the CC or CT genotype, a substantial portion of individuals with the TT genotype would benefit from a higher dose of FA to bring folate levels to the threshold (15 ng/mL) in order to achieve desirable tHcy reduction.
Discussion
This study investigates the interactive effect of the MTHFR C677T gene variant and serum folate levels on the serum tHcy-lowering response to long-term FA supplementation, using individual data from the CSPPT, a large, randomized trial in a population without mandatory FA fortification. 29 The CSPPT obtained individual data on the MTHFR C677T genotype, serum folate, and tHcy levels, as well as other important factors at baseline and exit visits, providing a rare opportunity to comprehensively evaluate the effect modifiers of the tHcy-lowering response to FA treatment. From this study, we have gained important new insights regarding MTHFR gene-FA interactions on the tHcy-lowering response to FA therapy, and it provides new evidence to support a personalized FA treatment.
We found that 0.8 mg/d FA therapy can effectively increase serum folate levels and reduce tHcy levels by 11%, on average. However, there was substantial variation by the MTHFR C677T genotype. With 0.8 mg/d FA treatment, ≈30% of participants with the TT genotype did not achieve a folate threshold of ≥15 ng/mL, and only ≈20% from the TT group achieved a tHcy <10 μmol/L at the exit visit, suggesting that there is room to further fine-tune the FA regimen.
Most importantly, our analyses revealed a remarkable interactive effect of the MTHFR C677T polymorphism and serum folate levels on tHcy levels. There was an L-shaped association between tHcy and serum folate levels, which was most prominent for the TT genotype when folate levels were low. With higher levels of serum folate, the effect of the TT genotype on tHcy diminished and approached zero when folate levels reached around 15 ng/mL or 34 nmol/L, indicating a threshold effect of folate levels to overcome the TT genotype-induced elevation of tHcy. Of note, a further increase in folate levels above this threshold did not confer additional benefits, indicating a ceiling effect as well.
Our findings were based on individual data and are consistent with those of a previous meta-analysis 33 based on ecological data (stratified by regions with low versus high Figure 2 . The relationships between baseline serum total homocysteine (tHcy) levels and folate levels varied by methylenetetrahydrofolate reductase (MTHFR) C677T genotypes. A total of 16 413 subjects with both baseline and exit tHcy and folate measurements were included in the analyses. Smoothing curves were drawn between tHcy levels and serum folate levels at baseline (A) and exit (B).
folate intake). The latter showed that the effect of the MTHFR 677TT variant compared with the CC genotype was larger in low folate regions like Asia than in areas with folate fortification (America, Australia, and New Zealand). The probable mechanism may be related to defective MTHFR enzymes in individuals with the TT genotype. Enzyme function is reduced to ≈65% of normal in individuals heterozygous for the MTHFR C677T polymorphism (CT genotype). In those who are homozygous for the mutation (TT genotype), enzyme function is only 30% of normal. 9 Most exciting, our data provide evidence that nutrition can counteract genetic susceptibility. Specifically, we demonstrated that the adverse effect of the TT genotype on tHcy levels can be ameliorated by raising serum folate levels above the threshold (15 ng/mg or 34 nmol/L) via FA treatment. Our study made 2 important observations: (1) the MTHFR C677T polymorphism modifies the tHcy-lowering response to FA treatment 34 and (2) this modifying effect is dependent on serum folate levels. Our data suggest that individuals with the TT genotype and low serum folate tend to have the highest levels of tHcy; however, this subgroup benefits the most from FA therapy, in particular, when serum folate levels reach the threshold where, we have found, the TT genotypeinduced elevation of tHcy levels can be eliminated. There are over 1 billion hypertensive patients in the world. 35 Studies have shown that hypertension accompanied by elevated tHcy can synergistically increase the risk of cardiovascular disease and stroke. 3, [36] [37] [38] [39] [40] Furthermore, in a recent analysis from the CSPPT, we showed that elevated tHcy also reduced the efficacy of antihypertensive drug. 41 Our findings suggest a need for a new strategy to personalize FA therapy to optimize tHcy lowering, which has important clinical, public health, and research implications.
Our findings have implications beyond the Chinese population. The MTHFR 677TT variant is a risk factor for cardiovascular disease 42, 43 with a frequency that ranges from 11.6% in non-Hispanic whites to 19.4% in Mexican Americans but is less common in non-Hispanic blacks (1.2%). 9 Among individuals with the TT genotype, our study showed that a folate threshold of ≈15 ng/mL or 34 nmol/L, which is about the median level of the current US population according to NHANES (National Health and Nutrition Examination Surveys) data, 44 is necessary to overcome the MTHFR enzyme defects. It is likely that even in a FA-fortified country like the United States, many individuals with the TT genotype may have folate levels below the threshold and, therefore, need additional folate supplementation to ameliorate the MTHFR enzyme defect. In countries without FA fortification such as China, >70% of those with the TT genotype have serum folate levels below the threshold and would require FA supplementation to raise their folate levels to the threshold level.
Several potential limitations are noted. First, this study focused on hypertensive adults, and the generalizability of our results to nonhypertensive adults remains to be determined. Second, we only measured tHcy at 2 time points (baseline and exit visits) and did not collect tHcy measurements during the follow-up period. Finally, this is a post hoc analyses, and our findings can only serve as hypothesis-generating, and additional investigation is warranted.
Conclusions
Our study showed that long-term daily 0.8-mg FA therapy reduced tHcy levels by 11% on average in Chinese hypertensive patients without pre-existing myocardial infarction Figure 3 . Mean differences in serum total homocysteine (tHcy) levels between methylenetetrahydrofolate reductase (MTHFR) 677TT and CC (A) and between MTHFR 677TT and CT (B) genotypes according to exit serum folate levels. A total of 16 413 subjects with exit tHcy and folate measurements were included in the analyses. The difference in tHcy levels between TT and CT/CC genotypes was large when folate levels were low but approached zero when folate levels reached ≥15 ng/mL. CI indicates confidence interval. or stroke. More importantly, the degree of tHcy lowering in response to FA treatment varied greatly by the MTHFR C677T genotype and serum folate levels. Our data suggest that higher serum folate levels (≥15 ng/L or 34 nmol/L) are required for individuals with the MTHFR 677TT variant to overcome MTHFR enzyme defects caused by the TT variant. If true, this group is also more likely to benefit from FA therapy compared with individuals with the CC or CT genotype. Although our findings remain to be confirmed in future studies, they raise the prospect for precision FA therapy that is tailored to individual folate levels and genetic background (both biomarkers are easy to obtain). By prescribing appropriate doses of FA according to individual need, the ability to lower tHcy will improve while avoiding excessive FA supplementation in light of its ceiling effect and potential adverse effects at excessive levels.
